Tahara E, Shimamoto F, Taniyama K, Ito H, Kosako Y, Sumiyoshi H
Cancer Res. 1982 May;42(5):1781-7.
This study deals with the effects of gastrin on the incidence of gastric tumors in rats induced by N-methyl-N'-nitro-N-nitrosoguanidine. Inbred Basel-Wistar rats received N-methyl-N'-nitro-N-nitrosoguanidine in drinking water (50 micrograms/ml for 32 weeks) in order to produce gastric carcinoids. A treatment with s.c. injection of pentagastrin (300 micrograms/kg, once daily for 4 weeks) was started at the beginning of N-methyl-N'-nitro-N-nitrosoguanidine treatment simultaneously, on the 4th, 8th, 16th, and 32nd week after start of N-methyl-N'-nitro-N-nitrosoguanidine treatment, respectively. At autopsy, from the 55th to 60th week after start of the experiment, only in the eighth-week group of gastrin-treated rats was the incidence of gastric carcinoid significantly higher than in the gastrin-untreated group of rats receiving N-methyl-N'-nitro-N-nitrosoguanidine alone. The incidence of adenocarcinoma in the glandular stomach also was high only in the fourth-week group of gastrin-treated rats. However, these effects could not be seen in other gastrin-treated or untreated groups of rats. The data suggest that gastrin treatment in the early stage of rat stomach carcinogenesis by N-methyl-N'-nitro-N-nitrosoguanidine is effective in increasing the development of gastric tumors.
本研究探讨了胃泌素对N-甲基-N'-硝基-N-亚硝基胍诱导的大鼠胃肿瘤发生率的影响。近交系巴塞尔-威斯塔大鼠饮用含N-甲基-N'-硝基-N-亚硝基胍的水(50微克/毫升,持续32周)以诱发胃类癌。在开始给予N-甲基-N'-硝基-N-亚硝基胍治疗的同时,于开始治疗的第4周、第8周、第16周和第32周分别皮下注射五肽胃泌素(300微克/千克,每日一次,共4周)进行治疗。在实验开始后的第55至60周进行尸检时,仅在接受胃泌素治疗的第8周组大鼠中,胃类癌的发生率显著高于仅接受N-甲基-N'-硝基-N-亚硝基胍治疗的未接受胃泌素治疗的大鼠组。腺胃腺癌的发生率也仅在接受胃泌素治疗的第4周组大鼠中较高。然而,在其他接受胃泌素治疗或未接受治疗的大鼠组中未观察到这些效应。数据表明,在N-甲基-N'-硝基-N-亚硝基胍诱发大鼠胃癌发生的早期阶段给予胃泌素治疗,可有效促进胃肿瘤的发生发展。